Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization
Yuji Ito, … , F. Patrick Ross, Haibo Zhao
Yuji Ito, … , F. Patrick Ross, Haibo Zhao
Published May 24, 2010
Citation Information: J Clin Invest. 2010;120(6):1981-1993. https://doi.org/10.1172/JCI39650.
View: Text | PDF
Research Article Bone biology Article has an altmetric score of 1

Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization

  • Text
  • PDF
Abstract

The modeling and remodeling of bone requires activation and polarization of osteoclasts, achieved by reorganization of the cytoskeleton. Members of the Rho subfamily of small GTPases, including Cdc42, are known regulators of cytoskeletal components, but the role of these proteins in bone physiology and pathophysiology remains unclear. Here, we examined loss-of-function mice in which Cdc42 was selectively ablated in differentiated osteoclasts and gain-of-function animals wherein Cdc42Gap, a protein that inactivates the small GTPase, was deleted globally. Cdc42 loss-of-function mice were osteopetrotic and resistant to ovariectomy-induced bone loss, while gain-of-function animals were osteoporotic. Isolated Cdc42-deficient osteoclasts displayed suppressed bone resorption, while osteoclasts with increased Cdc42 activity had enhanced resorptive capacity. We further demonstrated that Cdc42 modulated M-CSF–stimulated cyclin D expression and phosphorylation of Rb and induced caspase 3 and Bim, thus contributing to osteoclast proliferation and apoptosis rates. Furthermore, Cdc42 was required for multiple M-CSF– and RANKL-induced osteoclastogenic signals including activation and expression of the differentiation factors MITF and NFATc1 and was a component of the Par3/Par6/atypical PKC polarization complex in osteoclasts. These data suggest that Cdc42 regulates osteoclast formation and function and may represent a promising therapeutic target for prevention of pathological bone loss.

Authors

Yuji Ito, Steven L. Teitelbaum, Wei Zou, Yi Zheng, James F. Johnson, Jean Chappel, F. Patrick Ross, Haibo Zhao

×

Figure 7

Par-3/Par-6/aPKCs complex mediates Cdc42-regulated osteoclast polarization.

Options: View larger image (or click on image) Download as PowerPoint
Par-3/Par-6/aPKCs complex mediates Cdc42-regulated osteoclast polarizati...
(A) RANKL stimulates threonine and tyrosine phosphorylation of aPKCs in mature osteoclasts. Mature osteoclasts, generated by 5 days’ exposure of WT BMMs to RANKL and M-CSF, were serum- and cytokine-starved and then treated with RANKL over time. Left: Lysates were immunoblotted for threonine-phosphorylated and total aPKC. Right: Lysates were immunoprecipitated for total phosphotyrosine (p-Y) using mAb 4G10 or aPKC. Immunoprecipitates were immunoblotted for aPKC. (B) Immunoprecipitation of endogenous aPKCs in osteoclasts transduced with empty vector (pMX), HA-tagged dominant-negative (Cdc42-17N), or HA-tagged constitutively active (Cdc42-12V) retroviruses. TCL: total cell lysates. (C) Co-immunoprecipitation of HA-tagged Par-6 with aPKCs and LGL in osteoclasts. (D) Co-immunoprecipitation of endogenous Par-3 in osteoclasts transduced with pMX, N-terminal–FLAG-tagged PKC-λ (N-FLAG-aPKC), or C-terminal–FLAG–tagged PKC-λ (C-FLAG-aPKC). (E) Co-immunoprecipitation of endogenous Par-3 in osteoclasts transduced with N-terminal HA-tagged par-6 (N-HA par-6) or C-terminal HA-tagged par-6 (C-HA par-6). (F) Selective inhibition of PKC isoforms in mature osteoclasts, cultured on bone slices, by 1 hour exposure to cell-permeable pseudo substrate (PS) peptide inhibitors of PKC-α, PKC-θ, PKC-ε, PKC-ζ, and Go 6976. (G) Osteoclasts were incubated with PKC-ζ inhibitor or carrier for 1 hour followed by washing and cultured for 1 or 3 hours. Cells were stained to visualize actin rings. Hoechst stain visualizes nuclei. Original magnification, ×200. (H) Quantification of the percentage of osteoclasts exhibiting actin rings illustrated in F (***P < 0.001).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Highlighted by 1 platforms
76 readers on Mendeley
See more details